Listed

Bristol Myers Squibb Co

BMYNYSECIK 14272HealthcareFiscal year ends Dec 31

Latest reported revenue, Q2 FY2026$12.97bnRevenue, Q2 FY2026, three months to 2026-06-30$12.97bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figureThree months to Jun 30, 2026, from the 10-Q filed Jul 30, 2026.

Latest quarter: Q2 FY2026

Three months to Jun 30, 2026, against the same quarter a year earlier.

  • Revenue$12.97bnRevenue, Q2 FY2026, three months to 2026-06-30$12.97bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figure+5.7% on a year earlier
  • Gross marginnot reported (Gross profit not reported)No year-earlier figure to compare
  • Operating marginnot reported (Operating income not reported)No year-earlier figure to compare
  • Net margin25.6%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $3.32bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Revenue: $12.97bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figure+14.9 pts on a year earlier
  • Diluted EPS$1.62Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figure+153.1% on a year earlier
  • Free cash flow$3.09bnFree cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $3.39bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0000014272-26-000020. Derived: 6-month figure less the 3-month figure.Capital expenditure: $305.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0000014272-26-000020. Derived: 6-month figure less the 3-month figure.Report this figure−13.2% on a year earlier

Last eight quarters

Full statements
Revenue$12.97bnNet margin 25.6%
Diluted EPS$1.62, Q2 FY2026
Free cash flow$3.09bn, Q2 FY2026
Bristol Myers Squibb Co, key figures for the last eight quarters
Line itemUnitQ3 FY20242024-09-30Q4 FY20242024-12-31Q1 FY20252025-03-31Q2 FY20252025-06-30Q3 FY20252025-09-30Q4 FY20252025-12-31Q1 FY20262026-03-31Q2 FY20262026-06-30Shape over the periods
Revenue$bn11.9Revenue, Q3 FY2024, three months to 2024-09-30$11.89bn. XBRL concept us-gaap:Revenues. 10-Q filed 2025-10-30, accession 0000014272-25-000149.Report this figure12.3Revenue, Q4 FY2024, three months to 2024-12-31$12.34bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure11.2Revenue, Q1 FY2025, three months to 2025-03-31$11.20bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Report this figure12.3Revenue, Q2 FY2025, three months to 2025-06-30$12.27bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figure12.2Revenue, Q3 FY2025, three months to 2025-09-30$12.22bn. XBRL concept us-gaap:Revenues. 10-Q filed 2025-10-30, accession 0000014272-25-000149.Report this figure12.5Revenue, Q4 FY2025, three months to 2025-12-31$12.50bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure11.5Revenue, Q1 FY2026, three months to 2026-03-31$11.49bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Report this figure13.0Revenue, Q2 FY2026, three months to 2026-06-30$12.97bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)
Net margin%10.2%Net margin, Q3 FY2024, three months to 2024-09-30. net income / revenueNet income: $1.21bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0000014272-25-000149.Revenue: $11.89bn. XBRL concept us-gaap:Revenues. 10-Q filed 2025-10-30, accession 0000014272-25-000149.Report this figure0.6%Net margin, Q4 FY2024, three months to 2024-12-31. net income / revenueNet income: $72.0m. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $12.34bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure21.9%Net margin, Q1 FY2025, three months to 2025-03-31. net income / revenueNet income: $2.46bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Revenue: $11.20bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Report this figure10.7%Net margin, Q2 FY2025, three months to 2025-06-30. net income / revenueNet income: $1.31bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Revenue: $12.27bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figure18.0%Net margin, Q3 FY2025, three months to 2025-09-30. net income / revenueNet income: $2.20bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2025-10-30, accession 0000014272-25-000149.Revenue: $12.22bn. XBRL concept us-gaap:Revenues. 10-Q filed 2025-10-30, accession 0000014272-25-000149.Report this figure8.7%Net margin, Q4 FY2025, three months to 2025-12-31. net income / revenueNet income: $1.09bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Revenue: $12.50bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure23.3%Net margin, Q1 FY2026, three months to 2026-03-31. net income / revenueNet income: $2.68bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Revenue: $11.49bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Report this figure25.6%Net margin, Q2 FY2026, three months to 2026-06-30. net income / revenueNet income: $3.32bn. XBRL concept us-gaap:NetIncomeLoss. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Revenue: $12.97bn. XBRL concept us-gaap:Revenues. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figure
Diluted EPS$ per share0.60Diluted EPS, Q3 FY2024, three months to 2024-09-30$0.60 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0000014272-25-000149.Report this figurenot reported (Diluted EPS not reported)1.20Diluted EPS, Q1 FY2025, three months to 2025-03-31$1.20 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Report this figure0.64Diluted EPS, Q2 FY2025, three months to 2025-06-30$0.64 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figure1.08Diluted EPS, Q3 FY2025, three months to 2025-09-30$1.08 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2025-10-30, accession 0000014272-25-000149.Report this figurenot reported (Diluted EPS not reported)1.31Diluted EPS, Q1 FY2026, three months to 2026-03-31$1.31 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Report this figure1.62Diluted EPS, Q2 FY2026, three months to 2026-06-30$1.62 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-Q filed 2026-07-30, accession 0000014272-26-000020.Report this figure
Free cash flow$bn5.3Free cash flow, Q3 FY2024, three months to 2024-09-30. operating cash flow − capital expenditureOperating cash flow: $5.59bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0000014272-25-000149. Derived: 9-month figure less the 6-month figure.Capital expenditure: $324.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0000014272-25-000149. Derived: 9-month figure less the 6-month figure.Report this figure4.1Free cash flow, Q4 FY2024, three months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $4.44bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Capital expenditure: $378.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure1.7Free cash flow, Q1 FY2025, three months to 2025-03-31. operating cash flow − capital expenditureOperating cash flow: $1.95bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Capital expenditure: $260.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Report this figure3.6Free cash flow, Q2 FY2025, three months to 2025-06-30. operating cash flow − capital expenditureOperating cash flow: $3.92bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0000014272-26-000020. Derived: 6-month figure less the 3-month figure.Capital expenditure: $361.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0000014272-26-000020. Derived: 6-month figure less the 3-month figure.Report this figure6.0Free cash flow, Q3 FY2025, three months to 2025-09-30. operating cash flow − capital expenditureOperating cash flow: $6.31bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2025-10-30, accession 0000014272-25-000149. Derived: 9-month figure less the 6-month figure.Capital expenditure: $320.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2025-10-30, accession 0000014272-25-000149. Derived: 9-month figure less the 6-month figure.Report this figure1.6Free cash flow, Q4 FY2025, three months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $1.97bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Capital expenditure: $370.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000014272-26-000004. Derived: 12-month figure less the 9-month figure.Report this figure0.8Free cash flow, Q1 FY2026, three months to 2026-03-31. operating cash flow − capital expenditureOperating cash flow: $1.10bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Capital expenditure: $347.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-04-30, accession 0000014272-26-000010.Report this figure3.1Free cash flow, Q2 FY2026, three months to 2026-06-30. operating cash flow − capital expenditureOperating cash flow: $3.39bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-Q filed 2026-07-30, accession 0000014272-26-000020. Derived: 6-month figure less the 3-month figure.Capital expenditure: $305.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-Q filed 2026-07-30, accession 0000014272-26-000020. Derived: 6-month figure less the 3-month figure.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Last five fiscal years

Revenue$48.19bnNet margin 14.6%
Diluted EPS$3.46, FY2025
Free cash flow$12.85bn, FY2025
Bristol Myers Squibb Co, key figures for the last five fiscal years
Line itemUnitFY20212021-12-31FY20222022-12-31FY20232023-12-31FY20242024-12-31FY20252025-12-31Shape over the periods
Revenue$bn46.4Revenue, FY2021, twelve months to 2021-12-31$46.38bn. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-13, accession 0000014272-24-000044.Report this figure46.2Revenue, FY2022, twelve months to 2022-12-31$46.16bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-12, accession 0000014272-25-000039.Report this figure45.0Revenue, FY2023, twelve months to 2023-12-31$45.01bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure48.3Revenue, FY2024, twelve months to 2024-12-31$48.30bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure48.2Revenue, FY2025, twelve months to 2025-12-31$48.19bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure
Gross margin%not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)not reported (Gross profit not reported)
Operating margin%not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)not reported (Operating income not reported)
Net margin%15.1%Net margin, FY2021, twelve months to 2021-12-31. net income / revenueNet income: $6.99bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2024-02-13, accession 0000014272-24-000044.Revenue: $46.38bn. XBRL concept us-gaap:Revenues. 10-K filed 2024-02-13, accession 0000014272-24-000044.Report this figure13.7%Net margin, FY2022, twelve months to 2022-12-31. net income / revenueNet income: $6.33bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2025-02-12, accession 0000014272-25-000039.Revenue: $46.16bn. XBRL concept us-gaap:Revenues. 10-K filed 2025-02-12, accession 0000014272-25-000039.Report this figure17.8%Net margin, FY2023, twelve months to 2023-12-31. net income / revenueNet income: $8.03bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000014272-26-000004.Revenue: $45.01bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure(18.5%)Net margin, FY2024, twelve months to 2024-12-31. net income / revenueNet income: −$8.95bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000014272-26-000004.Revenue: $48.30bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure14.6%Net margin, FY2025, twelve months to 2025-12-31. net income / revenueNet income: $7.05bn. XBRL concept us-gaap:NetIncomeLoss. 10-K filed 2026-02-11, accession 0000014272-26-000004.Revenue: $48.19bn. XBRL concept us-gaap:Revenues. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure
Diluted EPS$ per share3.12Diluted EPS, FY2021, twelve months to 2021-12-31$3.12 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2024-02-13, accession 0000014272-24-000044.Report this figure2.95Diluted EPS, FY2022, twelve months to 2022-12-31$2.95 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2025-02-12, accession 0000014272-25-000039.Report this figure3.86Diluted EPS, FY2023, twelve months to 2023-12-31$3.86 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure(4.41)Diluted EPS, FY2024, twelve months to 2024-12-31−$4.41 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure3.46Diluted EPS, FY2025, twelve months to 2025-12-31$3.46 per share. XBRL concept us-gaap:EarningsPerShareDiluted. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure
Free cash flow$bn15.2Free cash flow, FY2021, twelve months to 2021-12-31. operating cash flow − capital expenditureOperating cash flow: $16.21bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2024-02-13, accession 0000014272-24-000044.Capital expenditure: $973.0m. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2024-02-13, accession 0000014272-24-000044.Report this figure11.9Free cash flow, FY2022, twelve months to 2022-12-31. operating cash flow − capital expenditureOperating cash flow: $13.07bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2025-02-12, accession 0000014272-25-000039.Capital expenditure: $1.12bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2025-02-12, accession 0000014272-25-000039.Report this figure12.7Free cash flow, FY2023, twelve months to 2023-12-31. operating cash flow − capital expenditureOperating cash flow: $13.86bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000014272-26-000004.Capital expenditure: $1.21bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure13.9Free cash flow, FY2024, twelve months to 2024-12-31. operating cash flow − capital expenditureOperating cash flow: $15.19bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000014272-26-000004.Capital expenditure: $1.25bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure12.8Free cash flow, FY2025, twelve months to 2025-12-31. operating cash flow − capital expenditureOperating cash flow: $14.16bn. XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities. 10-K filed 2026-02-11, accession 0000014272-26-000004.Capital expenditure: $1.31bn. XBRL concept us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. 10-K filed 2026-02-11, accession 0000014272-26-000004.Report this figure

Focus or hover a figure to see its XBRL concept, period and filing; each links to that filing. A figure marked d is derived: a quarter computed from year-to-date figures, such as the fourth quarter as the fiscal year less the nine months before it. A ratio reads not reported when any input is missing.

Insider purchases and sales

All insider transactions

The last 20 open-market transactions reported on Form 4 (codes P and S). The reported price is the price per share the insider stated on the form: filing data, not a market price.

No open-market purchases or sales by insiders are in coverage from Nov 2024 to Oct 2026.

No open-market purchases or sales by insiders are in coverage for this company.

Funds that report holding it

All funds

From each manager's latest Form 13F, largest reported value first. Reported value is as filed at the quarter end: filing data, not a price. A put or call is an option position, not shares held.

Funds that report holding Bristol Myers Squibb Co
FundQuarter endedReported valueSharesPut or callChange on the quarter before
BlackRock, Inc.2026-06-30$10.39bn180,384,994Added+8,702,106
VANGUARD CAPITAL MANAGEMENT LLC2026-06-30$7.68bn133,337,856Added+1,017,616
STATE STREET CORP2026-06-30$5.90bn102,408,940Added+3,844,026
JPMORGAN CHASE & CO2026-06-30$4.20bn71,713,442Reduced−20,761,752
CHARLES SCHWAB INVESTMENT MANAGEMENT INC2026-06-30$3.89bn67,595,177Added+6,479,804
GEODE CAPITAL MANAGEMENT, LLC2026-06-30$3.24bn56,443,077Added+1,156,903
VANGUARD PORTFOLIO MANAGEMENT LLC2026-06-30$2.70bn46,873,015Added+642,860
NORGES BANK2026-06-30$2.12bn36,866,658New+36,866,658
BANK OF AMERICA CORP /DE/2026-06-30$1.96bn34,045,352Added+1,458,371
MORGAN STANLEY2026-06-30$1.67bn29,009,025Reduced−189,529

Recent filings

All 2,590 filings

Reports and events: 10-K, 10-Q, 8-K, proxy statements and ownership schedules.

Bristol Myers Squibb Co, recent filings
FiledFormWhat it isAccession number
2026-10-2907:05 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000014272-26-000022
2026-07-3011:10 ET10-QQuarterly reportPeriod 2026-06-300000014272-26-000020
2026-07-3007:05 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000014272-26-000018
2026-05-0816:10 ET8-K5.07 Shareholder vote results0001140361-26-020036
2026-04-3011:44 ET10-QQuarterly reportPeriod 2026-03-310000014272-26-000010
2026-04-3007:01 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000014272-26-000008
2026-03-2516:19 ETDEF 14AProxy statementPeriod 2026-05-050000014272-26-000006
2026-02-1111:35 ET10-KAnnual reportPeriod 2025-12-310000014272-26-000004
2026-02-0507:07 ET8-K2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0000014272-26-000002
2026-01-1210:20 ET8-K7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits0001140361-26-000929

Latest annual report

Form 10-K for the fiscal year ended Dec 31, 2025Filed Feb 11, 2026. Its page lists the documents and the extracted sections, such as Business and Risk factors.

Forecast league

Q3 FY2026, the quarter ended 2026-09-30, locked when the 8-K was accepted. It is scored when the 10-Q or 10-K is ingested.See the target

About the filer

CIK
14272
Tickers
BMY, CELG-RI
Exchange
NYSE
SIC code
2834 Pharmaceutical Preparations
Sector
Healthcare
Fiscal year ends
Dec 31
Incorporated in
DE
Filer category
Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 29, 2026, 11:17 ET. Listed shows no prices and gives no investment advice.